Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients
- 1 June 2017
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 76 (6) , 1189-1191
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- European S1 guideline for the treatment of hidradenitis suppurativa/acne inversaJournal of the European Academy of Dermatology and Venereology, 2015
- A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in AdultsArchives of Dermatology, 2012
- Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo studyBritish Journal of Dermatology, 2011
- Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesTherapeutic Advances in Musculoskeletal Disease, 2010
- Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology, 2010